A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Celiac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics




TekijätKalliokoski S, Sulic AM, Korponay-Szabo IR, Szondy Z, Frias R, Perez MA, Martucciello S, Roivainen A, Pelliniemi LJ, Esposito C, Griffin M, Sblattero D, Maki M, Kaukinen K, Lindfors K, Caja S

KustantajaPUBLIC LIBRARY SCIENCE

Julkaisuvuosi2013

JournalPLoS ONE

Tietokannassa oleva lehden nimiPLOS ONE

Lehden akronyymiPLOS ONE

Artikkelin numeroARTN e65887

Numero sarjassa6

Vuosikerta8

Numero6

Sivujen määrä8

ISSN1932-6203

DOIhttps://doi.org/10.1371/journal.pone.0065887


Tiivistelmä
A characteristic feature of celiac disease is the presence of circulating autoantibodies targeted against transglutaminase 2 (TG2), reputed to have a function in angiogenesis. In this study we investigated whether TG2-specific autoantibodies derived from celiac patients inhibit angiogenesis in both ex vivo and in vivo models and sought to clarify the mechanism behind this phenomenon. We used the ex vivo murine aorta-ring and the in vivo mouse matrigel-plug assays to address aforementioned issues. We found angiogenesis to be impaired as a result of celiac disease antibody supplementation in both systems. Our results also showed the dynamics of endothelial cells was affected in the presence of celiac antibodies. In the in vivo angiogenesis assays, the vessels formed were able to transport blood despite impairment of functionality after treatment with celiac autoantibodies, as revealed by positron emission tomography. We conclude that celiac autoantibodies inhibit angiogenesis ex vivo and in vivo and impair vascular functionality. Our data suggest that the anti-angiogenic mechanism of the celiac disease-specific autoantibodies involves extracellular TG2 and inhibited endothelial cell mobility.



Last updated on 2024-26-11 at 10:42